Affordable Access

Publisher Website

Screening for late-onset Pompe disease in Finland

Neuromuscular Disorders
DOI: 10.1016/j.nmd.2014.06.438
  • Pompe Disease
  • Glycogen Storage Disease Type Ii
  • Late-Onset
  • Screening
  • Medicine


Abstract Pompe disease (glycogen storage disease type II) is caused by autosomal recessive mutations in GAA gene. The estimated frequency of late-onset Pompe disease is around 1:60,000. However, only two infantile and one late-onset Pompe patients have been reported in Finland with a population of 5 million. We screened for late-onset Pompe disease in a cohort of undetermined myopathy patients with proximal muscle weakness and/or elevated serum creatine kinase values. Acid α-glucosidase (GAA) activity in dried blood spots was measured and clinical data collected in 108 patients. Four patients had low normal GAA activity; all the others had activities well within the normal range. Re-analyses of these patients did not reveal new Pompe patients. Our findings suggest that Pompe disease is extremely rare in Finland. Finland is an example of an isolated population with enrichment of certain mutations for genetic disorders and low occurrence of some autosomal recessive diseases.

There are no comments yet on this publication. Be the first to share your thoughts.


Seen <100 times

More articles like this

Late-onset Pompe's disease.

on Seminars in neurology November 2012

Late onset Pompe disease revealed by newborn scree...

on American journal of medical ge... May 2011

Screening for later-onset Pompe's disease in patie...

on Molecular Genetics and Metabol...
More articles like this..